MX2018014977A - Composiciones y metodos para formulaciones de alfavirus vivos atenuados. - Google Patents

Composiciones y metodos para formulaciones de alfavirus vivos atenuados.

Info

Publication number
MX2018014977A
MX2018014977A MX2018014977A MX2018014977A MX2018014977A MX 2018014977 A MX2018014977 A MX 2018014977A MX 2018014977 A MX2018014977 A MX 2018014977A MX 2018014977 A MX2018014977 A MX 2018014977A MX 2018014977 A MX2018014977 A MX 2018014977A
Authority
MX
Mexico
Prior art keywords
live
compositions
attenuated
methods
attenuated alphavirus
Prior art date
Application number
MX2018014977A
Other languages
English (en)
Inventor
Dan T Stinchcomb
Jill A Livengood
Laszlo Varga
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50489420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018014977(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of MX2018014977A publication Critical patent/MX2018014977A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Las modalidades en este documento se refieren a composiciones de y métodos para alfavirus atenuados. En ciertas modalidades, una composición de virus vivo atenuado incluye, pero no se limita a, uno o más alfavirus vivos atenuados y composiciones para reducir la inactivación y/o degradación del alfavirus vivo atenuado. En otras modalidades, la composición de virus vivo atenuado puede ser una composición de vacuna. En otras composiciones, una composición de alfavirus vivo atenuado puede incluir tampón de HEPES. En otras modalidades, el tampón de HEPES puede incluir además un carbohidrato y gelatina y/o una sal.
MX2018014977A 2013-03-14 2015-09-14 Composiciones y metodos para formulaciones de alfavirus vivos atenuados. MX2018014977A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361784122P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
MX2018014977A true MX2018014977A (es) 2022-06-27

Family

ID=50489420

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015012894A MX361342B (es) 2013-03-14 2014-03-13 Composiciones y metodos para formulaciones de alfavirus vivos atenuados.
MX2018014977A MX2018014977A (es) 2013-03-14 2015-09-14 Composiciones y metodos para formulaciones de alfavirus vivos atenuados.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015012894A MX361342B (es) 2013-03-14 2014-03-13 Composiciones y metodos para formulaciones de alfavirus vivos atenuados.

Country Status (20)

Country Link
US (2) US10137186B2 (es)
EP (2) EP3603667A1 (es)
JP (3) JP6426695B2 (es)
KR (1) KR20160003662A (es)
CN (2) CN105377293B (es)
AP (1) AP2015008733A0 (es)
AU (2) AU2014236804B2 (es)
BR (1) BR112015023205A2 (es)
CA (1) CA2903711A1 (es)
CR (1) CR20150553A (es)
DO (1) DOP2015000226A (es)
EC (1) ECSP20007842A (es)
HK (1) HK1220358A1 (es)
MX (2) MX361342B (es)
MY (1) MY178476A (es)
NZ (1) NZ631012A (es)
PH (1) PH12015502115B1 (es)
SG (3) SG10201909051QA (es)
TW (2) TWI649087B (es)
WO (1) WO2014151855A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201909051QA (en) * 2013-03-14 2019-11-28 Takeda Vaccines Inc Compositions and methods for live, attenuated alphavirus formulations
EP3087188A1 (en) 2013-12-23 2016-11-02 Theravectys Lyophilized lentiviral vector particles, compositions and methods
WO2017172643A1 (en) * 2016-03-31 2017-10-05 Takeda Vaccines, Inc. Compositions and methods for stabilizing alphaviruses with improved formulations
NL2022538B1 (en) * 2019-02-08 2020-08-19 Academisch Ziekenhuis Groningen Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof.
CA3174826A1 (en) * 2021-01-19 2022-07-28 Katsuro HAGIWARA Virus stabilizer, gelatin hydrolysate for virus stabilizer, and virus-containing composition

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
RU2035508C1 (ru) * 1991-08-16 1995-05-20 Институт органической химии СО РАН Питательная среда для стабилизации вируса венесуэльского энцефалита лошадей
US5545555A (en) * 1994-07-25 1996-08-13 Microtest, Inc. Microbial transport media
WO1996017072A2 (en) * 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US6458560B1 (en) * 1996-04-05 2002-10-01 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6290967B1 (en) * 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
EP1100944A1 (en) * 1998-07-30 2001-05-23 The Johns Hopkins University School Of Medicine Targeted alphavirus and alphaviral vectors
US6869907B2 (en) * 2000-05-02 2005-03-22 Pentax Corporation Color-image-forming medium
FR2814957B1 (fr) 2000-10-06 2002-12-20 Aventis Pasteur Composition vaccinale et procede de stabilisation
EP1453537A1 (en) * 2001-12-12 2004-09-08 FH Faulding & Co. Limited Composition for viral preservation
WO2003087327A2 (en) * 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
US8603796B2 (en) 2003-12-17 2013-12-10 Wyeth Llc Method for producing storage stable viruses and immunogenic compositions thereof
CN101516395B (zh) * 2006-09-01 2014-03-26 伯哈拉特生物技术国际有限公司 抗屈曲病毒感染的疫苗
DK2099485T3 (en) * 2006-11-03 2018-05-22 Alphavax Inc Alphavirus and alphavirus replica particle formulations and associated methods
TWI417113B (zh) 2006-11-07 2013-12-01 Acambis Inc 以凍乾法穩定疫苗
AU2008279576C1 (en) 2007-04-06 2014-01-23 Takeda Vaccines, Inc. Methods and compositions for live attenuated viruses
CA2698392C (en) 2007-09-04 2019-12-03 Baoming Jiang Thermal inactivation of rotavirus
KR101679812B1 (ko) 2007-09-14 2016-11-28 사노피 파스테르 바이오로직스, 엘엘씨 클로스트리듐 디피실리 톡소이드 ａ 및 ｂ를 포함하는 약학적 조성물
EP3085787B1 (en) 2008-01-24 2020-10-28 The Board of Regents of the University of Texas System Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
EP2376107B1 (en) 2008-12-09 2014-05-21 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
EP2519539A4 (en) 2009-12-28 2013-11-13 Ligocyte Pharmaceuticals Inc METHODS FOR STABILIZING VIRUS-LIKE PARTICULATE SOLUTIONS BASED ON INFLUENZA-INFLUENZA-VIRUSED VIRUSES
CN102939104A (zh) 2010-06-01 2013-02-20 诺华有限公司 用冻干浓缩疫苗抗原
SG10201909051QA (en) 2013-03-14 2019-11-28 Takeda Vaccines Inc Compositions and methods for live, attenuated alphavirus formulations

Also Published As

Publication number Publication date
KR20160003662A (ko) 2016-01-11
US10806781B2 (en) 2020-10-20
JP2016513658A (ja) 2016-05-16
JP6761015B2 (ja) 2020-09-23
US10137186B2 (en) 2018-11-27
SG11201507462QA (en) 2015-10-29
SG10201801459SA (en) 2018-03-28
CN105377293B (zh) 2020-07-17
JP2019031543A (ja) 2019-02-28
DOP2015000226A (es) 2016-02-29
AP2015008733A0 (en) 2015-09-30
ECSP20007842A (es) 2020-09-30
HK1220358A1 (zh) 2017-05-05
SG10201909051QA (en) 2019-11-28
NZ631012A (en) 2017-08-25
CA2903711A1 (en) 2014-09-25
PH12015502115A1 (en) 2016-01-25
AU2018236897B2 (en) 2020-09-10
TW201900192A (zh) 2019-01-01
AU2018236897A1 (en) 2018-10-18
CR20150553A (es) 2015-12-01
MX2015012894A (es) 2016-04-04
AU2014236804A1 (en) 2015-10-01
BR112015023205A2 (pt) 2017-07-18
PH12015502115B1 (en) 2016-01-25
TW201513875A (zh) 2015-04-16
TWI649087B (zh) 2019-02-01
MX361342B (es) 2018-12-04
EP2968515A1 (en) 2016-01-20
EP2968515B1 (en) 2019-05-08
AU2014236804B2 (en) 2018-12-13
JP2020193231A (ja) 2020-12-03
US20140271715A1 (en) 2014-09-18
WO2014151855A1 (en) 2014-09-25
JP6426695B2 (ja) 2018-11-21
US20190134182A1 (en) 2019-05-09
CN105377293A (zh) 2016-03-02
MY178476A (en) 2020-10-14
CN111729077A (zh) 2020-10-02
EP3603667A1 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
ECSP20007842A (es) Composiciones y métodos para formulaciones de alfavirus vivos atenuados
CL2016001547A1 (es) Composiciones para el cuidado oral
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
PH12015502401A1 (en) Compositions and methods for enhancing microbial stability
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
GB2535876A (en) Absorbent clumping animal litter compositions
MX2015012737A (es) Vacunas de virus bovino liquidas estables.
MX2016004556A (es) Composicion de hueso comprimido y metodo para usar la misma.
PH12019501722A1 (en) Compositions and methods for promoting hair growth with mpc1 inhibitors
PH12017500627A1 (en) Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof
PH12018502120A1 (en) Live attenuated alphavirus constructs and methods and uses thereof
MX370488B (es) Prevencion de infecciones por staphylococcus aureus mediante vacunas de glucoproteina sintetizadas en escherichia coli.
MX2016012112A (es) Feromona tranquilizadora para gatos.
MX2019010101A (es) Composiciones y metodos para promover el crecimiento del cabello con inhibidores de mpc1.
MX358132B (es) Solucion de trombina y metodos de uso de esta.
PH12018502119A1 (en) Compositions and methods for stabilizing alphaviruses with improved formulations
MX2016011572A (es) Composiciones antimicrobianas de acido organico.
MX2017014971A (es) Composiciones de sal mejoradas y metodo de preparacion de las mismas.
IN2014MU00284A (es)
WO2018175580A3 (en) Development of an alternative modified live influenza b virus vaccine
AR095118A1 (es) Un procedimiento de inactivación viral en composición que comprende factor vii
MX2016001694A (es) Formulacion de vacuna de sacarido.
NZ708737A (en) Thrombin solution and methods of use thereof
TH179835A (th) องค์ประกอบและวิธีการสำหรับสูตรตำรับอัลฟาไวรัสซึ่งถูกทำให้อ่อนฤทธิ์ที่มีชีวิต